Purpose To determine if the pattern of retained contrast on immediate postprocedure computed tomography (CT) after particle embolization of hepatic tumors predicts modified Response Evaluation Criteria in Solid Tumors (mRECIST) response. Materials and Methods This study was approved by the Institutional Review Board with a waiver of authorization. One hundred four liver tumors were embolized with spherical embolic agents (Embospheres, Bead Block, LC Bead) and polyvinyl alcohol. Noncontrast CT was performed immediately after embolization to assess contrast retention in the targeted tumors, and treatment response was assessed by mRECIST criteria on follow-up CT (average time 9.0 ± 7.7 weeks after embolization). Tumor contrast retention (TCR) was determined based on change in Hounsfield units (HUs) of the index tumors between the preprocedure and immediate postprocedure scans; vascular contrast retention (VCR) was rated; and defects in contrast retention (DCR) were also documented. The morphology of residual enhancing tumor on follow-up CT was described as partial, circumferential, or total. Association between TCR variables and tumor response were assessed using multivariate logistic regression. Results Of 104 hepatic tumors, 51 (49 %) tumors had complete response (CR) by mRECIST criteria; 23 (22.1 %)
Introduction
Embolization and chemoembolization are widely applied therapies for unresectable hepatocellular carcinoma (HCC), neuroendocrine tumor liver metastases, and other hepatic metastases [1] [2] [3] [4] . Both embolization and chemoembolization take advantage of the fact that most hepatic malignancies derive their primary blood supply from the hepatic artery rather than the portal vein. Chemoembolization exploits the preferential arterial blood supply to hepatic tumors by selectively delivering high doses of chemotherapy intraarterially to the tumor bed [5, 6] . Embolization exploits the same preferential arterial blood supply to hepatic tumors to deliver calibrated spherical embolic agents to the tumor vasculature with the intent of causing terminal vessel occlusion, thus rendering hepatic tumors ischemic and subsequently devitalized [7, 8] . Since the 1990s, some centers have used small spherical embolic agents to maximize terminal vessel blockade [9] [10] [11] . Technological improvements in particle development has allowed interventionalists using embolization to match agents to patients based on particle properties, such as size, homogeneity [9] , and compressibility [12] .
Visualizing distribution of lipiodol after chemoembolization by fluoroscopy or computed tomography (CT) scan ensures accurate tumor targeting, and lipiodol retention has been shown to correlate with treatment response by multiple investigators dating back to the early 1990s [13, 14] . Particle delivery is indirectly monitored during embolization by suspending particles in contrast and observing the flow of contrast into the target vessels. After embolization, there is stasis of contrast within the tumor as well as the vessels that supply the tumor. After chemoembolization, follow-up CT has been shown to detail the distribution of lipiodol within the target tumor [15] . Although lipiodol accumulation in the target tumor on postchemoembolization imaging has been shown to be predictive of therapeutic efficacy [16, 17] , there has never been a report on the relevance of findings on immediate postprocedure CT after embolization without lipiodol. Given that contrast is retained by embolized tumor and is evident on immediate postembolization CT, we hypothesized that a similar predictive phenomenon could be identified after embolization without lipiodol. Because clinical therapeutic efficacy would take years to document, we chose to correlate contrast retention with radiologic findings of tumor necrosis in a pilot study. The goal of this study was to investigate whether the degree and morphology of contrast retention within the targeted tumor on immediate postprocedure CT after embolization of hepatic tumors can be used to predict subsequent modified Response Evaluation Criteria in Solid Tumors (mRECIST) response.
Materials and Methods

Subjects
A waiver of authorization was obtained from the Institutional Review Board for this retrospective study. Between February 2007 and March 2010, 63 patients underwent embolization treatment for unresectable liver tumors and were followed-up immediately by noncontrast CT scan. Embolization was chosen as treatment after discussion at a weekly multidisciplinary Hepatobiliary Disease Management Team meeting. Patients were excluded if they had undergone previous embolization or combined embolization/ablation (n = 17), had inappropriate preprocedure or follow-up imaging (n = 4), had treated tumors that did not meet mRECIST criteria for index tumor measurement (e.g., tumors \ 1 cm) (n = 7), or were lost to follow-up (n = 4). A total of 104 index tumors in the remaining 31 patients were included in this study. Patient demographics and tumor and embolization characteristics are listed in Table 1 . The patients ranged in age from 22 to 89 years (mean 64.06 ± 15.85). There were 16 men and 15 women. Pathology included 15 cases of HCC, 13 cases of neuroendocrine liver metastases, 1 case of HCC with concomitant neuroendocrine liver metastases, 1 case of adrenocortical carcinoma, and 1 case of medullary thyroid cancer. Diagnosis of the primary malignancy was confirmed by histology or by European Association for the Study of the Liver (EASL) criteria in the case of HCC.
Embolization Technique
The technique for embolization has been previously described [10, 11] . Briefly, hepatic angiography was performed from a common femoral approach with a 4F or 5F angiographic catheter to depict the hepatic artery anatomy, location of tumors, and portal vein patency. According to operator preference, Embosphere microspheres (40-120, 100-300, or 300-500 lm; Biosphere Medical, Rockland, MA), Bead Block (100-300 lm; Biocompatibles, Farnham, UK), or LC Bead (100-300 lm; Biocompatibles) loaded with 150 mg doxorubicin were suspended in 5-10 cc nonionic contrast and used for embolization. Bland embolization was performed in 29 patients (n = 99 tumors) and drug-eluting bead embolization was performed in 2 patients (n = 5 tumors). All vessels supplying the target tumor(s) were then selectively embolized to stasis. Stasis was defined as complete cessation of antegrade flow in the vessel supplying the tumor. In 21 cases, after initial embolization with one of these agents, polyvinyl alcohol (PVA) (100 lm) was used to achieve stasis in the parent artery, which was our consistent end point of embolization. Embolization was usually performed with a microcatheter. Staged procedures were used in patients with bilobar disease or sometimes for large ([10 cm) tumors. Patients were given antiemetic and antibiotic drugs before the procedure and for at least 24 h afterward.
Tumor Response Evaluation
All patients were evaluated by preprocedure contrastenhanced triple-phase helical CT scan within 30 days of embolization. The index tumors were identified and baseline measurements made. Immediate postprocedure noncontrast CT was performed with 20 min of completion of the last embolization procedure (after sheath removal and groin hemostasis) using a combined angio-CT system (Innova 4100/CT Lightspeed; GE Health Care). The next follow-up triphasic CT scan was performed 3-6 weeks after embolization. Follow-up imaging with triphasic CT continued approximately every 3 months. When evidence of significant residual or new arterial enhancing tumor was identified, repeat embolization was performed.
Tumor response was assessed on the follow-up CT images according to the mRECIST criteria [18] , which take lack of enhancement of the tumor into account. Unidimensional measurement of the longest diameter was recorded for each index tumor, which was selected according to mRECIST Cross-multiple segment 6 (5. [19, 20] . The morphology of residual enhancing tumor was described as partial, circumferential, or total.
Contrast Retention Evaluation
Contrast retention in the index liver tumors after embolization was described by assessing tumor contrast retention (TCR), vascular contrast retention (VCR [ Fig. 1 ]), and defects in contrast retention (DCR) on immediate postprocedure CT. TCR was based on the difference between HU of the treated tumor on immediate postembolization CT compared with preprocedure noncontrast CT. To determine TCR, the average HU of the tumor on CT with the maximum diameter was measured using an elliptical region of interest covering the majority of the tumor and subtracted from the average HU of the tumor on the immediate posttreatment scan. TCR was rated as follows: grade 0 = \30 HU increment; grade 1 = 30-60 HU increment; grade 2 = 60-120 HU increment; and grade 3 = [120 HU increment. VCR was defined as follows: grade 0 = no vessels filling around the tumor; grade 1 = Glisson's sheath filling; and grade 2 = arterial filling. DCR was defined as a peripheral defect in HU increase \30 HU that resulted in discontinuity in contrast enhancement in the periphery of the index tumor on immediate postprocedure CT. DCR was only assessed in tumors with grade 1-3 TCR because minimal tumor contrast retention seen in grade 0 TCR prevented assessment of peripheral defects in contrast retention. Assessment of contrast retention on postembolization CT and assessment of tumor response were made independently in a blinded fashion.
Statistics
Univariate analyses for response as outcome (CR vs. no CR) was performed using logistic regression on 104 index tumors for each contrast retention and patient/tumor characteristic variable. The correlation between TCR and VCR was assessed using Kendall's tau correlation coefficient. To identify the clinical factors jointly associated with response, a backward variable selection procedure was applied on all variables except DCR (not evaluable for patients with TCR grade 0) and catheter type (too sparse) with the variable retaining criteria of p B 0.05. To examine whether high contrast retention after embolization is desirable in both the target tumor (TCR) and the vasculature (VCR), three sets of multivariate models were developed each with TCR alone, VCR alone, and TCR ? VCR, adjusting for other statistically significant clinical factors identified using the variable selection procedure. Concordance index (C-index) was used to evaluate the models' discriminatory ability. C-index of 0.5 indicates no discrimination, and 1 indicates perfect discrimination. In addition, a separate model was built on the subset of patients with measures on defect of tumor contrast retention (DCR). Dependency between lesions in the same patient was accounted for by using generalized estimation equations. All analyses were performed in SAS (version 9.2; SAS, Cary, NC).
Results
During the investigation period, a total of 31 patients with 104 index tumors were treated in 32 embolization sessions. Tumor characteristics, including histopathology, size, density, location, and distribution, and the microspheres used for embolization are listed in Table 1 . Average time of follow-up CT scan used to assess mRECIST response was 9.0 ± 7.7 weeks after embolization (range 4-36). 
Contrast Retention and Tumor Response
Total necrosis by imaging (CR) was 6.9, 51.9, 70, and 77.8 % for TCR grade 0, 1, 2, and 3, respectively ( Table 2 , Fig. 2 ) and 22, 50, and 76.9 for VCR grade 0, 1, and 2, respectively (Figs. 3, 4) . DCR was assessed in the 75 of 104 tumors in which TCR was greater than grade 0; DCR could not be assessed in tumors with less robust contrast retention. CR rate was 90.6 % for tumors without DCR and 5.6 % when DCR was present. Data stratification by DCR showed that in the 57 tumors without DCR, CR was 66.7, 91.3, and 100 % for TCR 1, 2, and 3, respectively. Not surprisingly, TCR and VCR were correlated (Kendall's tau 0.48 p \ 0.0001) ( Table 3) . Tumors with TCR grade 1-3 were more often accompanied with Glisson's sheath or arterial filling around the index tumor than those with TCR grade 0. We examined the follow-up CT of patients with tumors that exhibited DCR to determine the morphology of the residual enhancing tumor on follow-up (Table 4) . Tumors with TCR grade 0 on postprocedure CT showed enhancing residual disease in the corresponding area on follow-up CT (22 of 29 tumors). In tumors where DCR was 
Predictors of CR
To determine the patient, tumor, and contrast retention variables associated with CR, univariate analyses were performed (Table 5) . TCR, VCR, and DCR were associated with CR in univariate analyses. Among other clinical factors, only tumor size and location were useful for predicting CR in univariate analysis.
Multivariate analysis (Table 6) showed that after adjusting for tumor size, TCR was strongly associated with radiologic CR, whereas tumors with lower grades of TCR were less likely to achieve this (overall p = 0.009); e.g., grade 2 vs. 3 TCR (OR 0.51; 95 % CI 0.18-1.42); grade 1 vs. 3 TCR (OR 0.27; 95 % CI 0.07-1.12); and grade 0 vs. 3 TCR (OR 0.01; 95 % CI 0-0.10). Similarly, after controlling for tumor size, VCR was associated with radiologic CR. Lower grades of VCR were also less likely to achieve this (second panel, Table 6 ). Because TCR and VCR were correlated, we created a joint multivariate model including both TCR and VCR as independent factors. Slightly attenuated ordinal effects remained for TCR and VCR in the multivariate model where both were included (third panel in Table 6 ). Nonetheless, the overall p value was 0.02 and 0.05 for TCR and VCR, respectively, in the joint model, suggesting that high contrast retention in both target tumor and vasculature is predictive of achieving radiologic CR. The TCR model had a higher concordance index than the VCR model: 0.85 vs. 0.79. The joint model had an even higher concordance index of 0.87. The increase of prediction accuracy was 0.06 from the VCR model to the TCR model and a less discernible 0.018 from the TCR model to the joint model. The results suggest that it is desirable to reach the highest grade of contrast retention in both target tumor and vasculature because the joint model further enhances prediction accuracy of a radiologic CR. Among 75 tumors where DCR could be measured, multivariate analysis (last panel in Table 6 ) suggested that both DCR and TCR were independent predictors of achieving a complete radiologic response (OR 0.005 [p \ 0.0001] and OR 0.11 [p \ 0.02], respectively).
Discussion
Predicting the results of embolization at the time of treatment can be challenging. In this study, using multivariate analysis we found that the imaging findings of TCR, VCR, and DCR of the index tumor(s) on immediate postprocedure CT embolization are all independent predictors of a radiologic CR on follow-up CT imaging using mRECIST criteria. TCR and VCR were positive predictors of mRE-CIST CR; DCR was a negative predictor of CR. Achieving at least grade 1 TCR without DCR resulted in an 84.2 % mRECIST CR rate; achieving grade 2 TCR without DCR resulted in a 94.4 % mRECIST CR rate. Based on our findings, to maximize the likelihood of CR per mRECIST criteria after embolization, the end point of embolization should be maximal contrast retention in both the tumor and feeding vasculature. Of note, our data suggest that an end point of embolization that aims to fill the tumor without filling its feeding vasculature would fail to take advantage of the independent increases in CR afforded by employing vascular stasis as the end point of embolization, which maximizes both VCR and TCR. In this study, DCR was a reliable predictor of recurrent disease. Our analysis of the residual tumor morphology provides some evidence for the etiology of treatment failures after embolization. Not surprisingly, we observed that less robust contrast retention in the index tumor on immediate follow-up C, tends to result in persistent enhancement of the entire tumor on subsequent follow-up CT. On follow-up imaging, tumors without DCR tend to result in total lack of enhancement (complete radiologic necrosis), whereas tumors with DCR tend to result in partial or circumferential residual enhancing tumor with the area of DCR corresponding to the region of subsequent recurrent tumor in 75 % (22 of 29) of patients.
Performing CT before the patient leaves the angiography suite enables the operator to adjust the treatment in real time. For example, if DCR is identified, other blood vessels (hepatic or nonhepatic) can be interrogated to determine if they supply the tumor, or ablation of the underembolized portion of the tumor could be performed. Spasm resulting from guidewire or catheter manipulation in a feeding vessel is another potential cause of a defect in contrast retention and embolization failure [21] . This could be considered at the time of treatment, if DCR is identified, and potentially reversed with vasodilators.
The findings in this study may also be relevant to chemoembolization with drug-eluting bead. Like embolization, drug-eluting bead embolization relies on the suspension of particles in contrast for treatment monitoring [22, 23] . Based on the results of this study, we suspect that TCR, VCR, and DCR on postembolization helical or conebeam CT [15] after drug-eluting bead embolization might also correlate with radiologic findings of necrosis. Performing this evaluation immediately after embolization when the patient is on the operating table enables the operator to adjust the treatment before the patient leaves the angiography suite.
To assess contrast retention at the time of embolization using the findings described in this study, a combined angio-CT system or cone-beam CT is needed so that CT can be performed without requiring the patient to move from the fluoroscopy suite to a dedicated CT room. This adds approximately 5-10 min to the procedure time and 500 mrem to the procedure dose. Multiple investigators have documented the advantage of intraprocedural CT hepatic angiography for prospectively identifying vessels supplying the target tumor [24, 25] .
This study has several limitations. Tumor response is based on follow-up CT imaging rather than histopathology. Lack of tumor enhancement on contrast-enhanced CT has been correlated with pathologic necrosis [18] , and the presence of arterial enhancement on CT is considered evidence of tumor viability [16] . Because we do not have long-term follow-up on this cohort of patients with various primary tumors, we cannot make claims regarding contrast retention and patient survival. We do plan to correlate TCR, VCR and DCR in future prospective studies with patient clinical outcome. Contrast retention in tumors and the corresponding arteries after particle embolization is temporary, and the kinetics of contrast wash-out is unknown. In this retrospective study, CT was performed within 20 min of conclusion of the final embolization. When multiple vessels were treated, it is quite possible that contrast begins to wash out from the tumors and vessels treated earlier in the procedure. It is conceivable that our few discrepant cases in which CR was achieved despite TCR grade 0 (6.9 %) or VCR grade 0 (22 %) are due to prolonged delay between completion of embolization of these tumors and immediate postembolization CT scan. Finally, in this retrospective study, a variety of particle sizes and types were used, and the tumor pathology was not uniform; the majority of tumors were treated with bland embolization. This raises the question of the general applicability of these results. 
Conclusion
After embolization, TCR, VCR, and DCR on immediate postembolization CT are independent predictors of radiologic complete response. Moderate to marked tumor contrast retention with Glisson's sheath filling or arterial filling without defect in contrast retention is an ideal end point of embolization. These findings suggest that, when available, CT (helical or cone-beam) performed immediately after embolization provides added clinical value. A defect in contrast retention should prompt careful review of preprocedure multiphasic and DSA imaging. This review could identify other vessels supplying the tumor that have not been treated or vessels that were previously in spasm, thus precluding delivery of embolic to the tumor. Whether complete treatment of the target tumor will affect survival remains to be investigated.
